CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 734 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02006654
NCT02006654Phase 3Completed
CompareCT.gov

Randomised, Double-blind, Parallel-group, Placebo-controlled Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor

H. Lundbeck A/S·interventional·Posted Dec 10, 2013·Updated Feb 7, 2018

In Brief

A Phase 3 clinical trial evaluating Placebo and Idalopirdine for Alzheimer's Disease. Completed, enrolled 734 participants across 107 sites in 15 countries.

Detailed Summary

To establish efficacy of idalopirdine as adjunctive therapy to acetylcholinesterase inhibitors (AChEIs) for symptomatic treatment of patients with mild-moderate Alzheimer's disease (AD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesAustralia, Brazil, Czechia, Germany, Israel, Mexico, Serbia, Singapore, Slovakia, South Korea, Spain, Switzerland, Turkey (Türkiye), United Kingdom, United States
CollaboratorsOtsuka Pharmaceutical Co., Ltd.

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 10, 2013
Enrollment StartMar 1, 2014
Primary CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 12.6 years ago

Interventions

Placebodrug

Once daily, matching placebo capsules, orally

Idalopirdinedrug

Once daily, encapsulated tablets, orally